{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:42:48Z","timestamp":1790779368256,"version":"4.1.0"},"reference-count":15,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["242146"],"award-info":[{"award-number":["242146"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["261060"],"award-info":[{"award-number":["261060"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["GN1834"],"award-info":[{"award-number":["GN1834"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["SP4650"],"award-info":[{"award-number":["SP4650"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Educ Pract Ed"],"accepted":{"date-parts":[[2016,7,6]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>The aminoglycosides are broad-spectrum, bactericidal antibiotics that are commonly prescribed for children, primarily for infections caused by Gram-negative pathogens. The aminoglycosides include gentamicin, amikacin, tobramycin, neomycin, and streptomycin. Gentamicin is the most commonly used antibiotic in UK neonatal units. Aminoglycosides are polar drugs, with poor gastrointestinal absorption, so intravenous or intramuscular administration is needed. They are excreted renally. Aminoglycosides are concentration-dependent antibiotics, meaning that the ratio of the peak concentration to the minimum inhibitory concentration of the pathogen is the pharmacokinetic-pharmacodynamic index best linked to their antimicrobial activity and clinical efficacy. However, due to their narrow therapeutic index, the patient\u2019s renal function should be monitored to avoid toxicity, and therapeutic drug monitoring is often required. Here we provide a review of aminoglycosides, with a particular focus on gentamicin, considering their pharmacokinetics and pharmacodynamics, and also practical issues associated with prescribing these drugs in a paediatric clinical setting.<\/jats:p>","DOI":"10.1136\/archdischild-2015-309069","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T22:43:24Z","timestamp":1470782604000},"page":"89-93","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":87,"title":["What do I need to know about aminoglycoside antibiotics?"],"prefix":"10.1136","volume":"102","author":[{"given":"Eva","family":"Germovsek","sequence":"first","affiliation":[{"name":"Inflammation, Infection and Rheumatology Section, UCL Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-5867","authenticated-orcid":false,"given":"Charlotte I","family":"Barker","sequence":"additional","affiliation":[{"name":"Inflammation, Infection and Rheumatology Section, UCL Institute of Child Health, London, UK"},{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"2025090700181547000_102.2.89.1","unstructured":"Martindale. The Complete Drug Reference. https:\/\/www.medicinescomplete.com\/mc\/martindale\/current\/1-a16-1-h.htm (accessed Apr 2016)."},{"key":"2025090700181547000_102.2.89.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.08.003"},{"key":"2025090700181547000_102.2.89.3","unstructured":"BNFC. British National Formulary for Children. http:\/\/www.evidence.nhs.uk\/formulary\/bnfc\/current\/5-infections\/51-antibacterial-drugs\/514-aminoglycosides (accessed Nov 2015)."},{"key":"2025090700181547000_102.2.89.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(03)00057-6"},{"key":"2025090700181547000_102.2.89.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"2025090700181547000_102.2.89.6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.1.93"},{"key":"2025090700181547000_102.2.89.7","unstructured":"Kent A , Kortsalioudaki C , Monahan IM , et al . Increasing MIC is associated with higher mortality in gentamicin treated neonatal gram negative infections. The 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) . Leipzig, Germany, 2015."},{"key":"2025090700181547000_102.2.89.8","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.878648"},{"key":"2025090700181547000_102.2.89.9","doi-asserted-by":"crossref","unstructured":"Rao SC , Srinivasjois R , Hagan R , et al . One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011;(11):CD005091. doi:10.1002\/14651858.CD005091.pub3","DOI":"10.1002\/14651858.CD005091.pub3"},{"key":"2025090700181547000_102.2.89.10","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.1.44.31924"},{"key":"2025090700181547000_102.2.89.11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr351"},{"key":"2025090700181547000_102.2.89.12","unstructured":"NPSA. National Patient Safety Agency. Safer use of intravenous gentamicin for neonates, 2010. http:\/\/www.nrls.npsa.nhs.uk\/alerts\/?entryid45=66271 (accessed Nov 2015)."},{"key":"2025090700181547000_102.2.89.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.01.002"},{"key":"2025090700181547000_102.2.89.14","doi-asserted-by":"crossref","unstructured":"Germovsek E , Kent A , Metsvaht T , et al . Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants. Antimicrob Agents Chemother 2016. doi:10.1128\/AAC.00577-16","DOI":"10.1128\/AAC.00577-16"},{"key":"2025090700181547000_102.2.89.15","doi-asserted-by":"publisher","DOI":"10.1177\/0115426507022002240"}],"container-title":["Archives of disease in childhood - Education &amp; practice edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2015-309069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:18:25Z","timestamp":1757229505000},"score":1,"resource":{"primary":{"URL":"https:\/\/ep.bmj.com\/lookup\/doi\/10.1136\/archdischild-2015-309069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,3,20]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/archdischild-2015-309069"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2015-309069","relation":{},"ISSN":["1743-0585","1743-0593"],"issn-type":[{"value":"1743-0585","type":"print"},{"value":"1743-0593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}